Effect of Metformin & Glutazon on cardiovascular disease

Not Applicable

• Conditions: Diabetes.; Diabetes mellitus; E10-14

• Registration Number: IRCT2013041311356N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

determination of Type 2 diabetes with ADA criteria (FBS=126 or HbA1C=6.5) and patients with newly diagnosed diabetes. Exclusion criteria: history of hurt failure; Creatine > 1.5 mg/dl; liver failure; history of malignancy and being treated with insulin or other glucose-lowering drugs.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adiponectin. Timepoint: firs study- last study. Method of measurement: blood sampling.;Osteoprotegrin. Timepoint: firs study- last study. Method of measurement: blood sampling.

Secondary Outcome Measures

Name	Time	Method
HbA1C. Timepoint: first study-last study. Method of measurement: Laboratory measurements of the HPLC method.;FPG. Timepoint: first study-last study. Method of measurement: Elisa.;HoMA-IR. Timepoint: first study-last study. Method of measurement: Fasting Insulin (µu/ml) ×FBS(mmol/l)/22/5.;BMI. Timepoint: first study-last study. Method of measurement: Scales - Height Gauges.;Creatinine. Timepoint: first study-last study. Method of measurement: Elisa.;TG. Timepoint: first study-last study. Method of measurement: Elisa.;Chol. Timepoint: first study-last study. Method of measurement: Elisa.;LDL. Timepoint: first study-last study. Method of measurement: Elisa.;HDL. Timepoint: first study-last study. Method of measurement: Elisa.